With close ties to Great Ormond Street Hospital and the UCL Great Ormond Street Institute of Child Health, GOSH Charity brings to C-Further leading expertise, networks, influence and deep connections to patient groups and families – building upon strong foundations aiming to become one of the fastest-growing child-first drug discovery pipelines.
The initial collaborative research projects selected for C-Further’s therapeutic pipeline will be revealed in the coming months.
The consortium invites like-minded organisations, researchers and funders within the childhood cancer community to visit the C-Further website and learn how to join this collaborative effort to make a difference for children and young people with cancer.
Aoife Regan, Director of Impact and Charitable Programmes at GOSH Charity, said:
"GOSH Charity is thrilled to join C-Further as a core partner, and we look forward to working closely with Cancer Research Horizons and LifeArc to identify new therapeutic project opportunities with the greatest impact for children and young people facing cancer. I’m confident that together, we can help to ensure promising treatments reach clinical trials and ultimately become available to children with the hardest to treat cancers. Alongside this exciting partnership and our ongoing appeal to build a new world-leading Children’s Cancer Centre at GOSH, we want to do everything we can to give children the best chance, and best childhood possible."
David Jenkinson, Head of Childhood Cancer at LifeArc, said:
"At C-Further, we aim to tackle major barriers preventing a step-change in outcomes for children and young people with cancer: the lack of drugs specifically designed for these cancers and the unique set of challenges this presents. With GOSH Charity’s renowned expertise, global network and deep ties to patients, C-Further is better positioned to collaborate with the community on systemic challenges and strengthen the innovation ecosystem for better outcomes for children and young people with cancer."
Tony Hickson, Chief Business Officer of Cancer Research Horizons, said:
"From its underlying biology to the long-term effects of treatment on growing bodies, children’s and young people’s cancer presents a unique set of challenges that require tailored approaches to research and drug development. Welcoming GOSH Charity as a C-Further core partner is a powerful step forward in our mission to ensure more children and young people live longer, better lives – free from the fear of cancer."
ENDS
About C-Further
C-Further is an international consortium of drug discovery and development researchers, clinicians, partners and impact investors with a shared commitment to creating new therapeutics for childhood cancers.
We envision a world where childhood cancers are treated effectively, with tailored, and well-tolerated treatments. Together we’re combining expertise from around the world to create an innovation ecosystem that allows us to challenge conventional approaches to developing therapies and accelerate promising ideas towards better outcomes for children living with cancer.
If you share this vision and believe you can contribute, we invite you to connect with us and be part of the change: [email protected]
About LifeArc
LifeArc is a not-for-profit medical research organisation that turns promising scientific research into impact for people living with rare diseases and Global Health infections.
We form partnerships and provide scientific expertise and funding to help break down the barriers preventing scientific breakthroughs from becoming life-transforming treatments and cures. We have been doing this for more than 30 years and our work has resulted in five licensed medicines, including cancer drug pembrolizumab and lecanemab for Alzheimer’s disease.
Our goal is a world where no one with a rare disease or a global infectious disease misses out on life-changing innovation because of complexity, cost or risk.
LifeArc is a company limited by guarantee (registered in England and Wales under no. 2698321) and a charity (registered in England and Wales under no. 1015243 and in Scotland under no. SC037861).
About GOSH Charity
Great Ormond Street Hospital Charity (GOSH Charity) stops at nothing to help give seriously ill children childhoods that are fuller, funner and longer. For the hundreds of children from all over the UK who are treated by Great Ormond Street Hospital (GOSH) every day, for children with rare or complex illnesses everywhere, for this generation and all those to come.
GOSH has been transforming the lives of seriously ill children since opening its doors in 1852 and has always depended on charitable support. GOSH Charity funds groundbreaking research into children’s health, cutting-edge medical equipment, child-centred medical facilities and the support services children and families going through the toughest journey of their lives urgently need. But there is so much more we need to do.
The new Children’s Cancer Centre at GOSH is under construction, supported by a £300 million fundraising appeal from GOSH Charity. The centre will provide state-of-the-art facilities and create an environment where cutting-edge research can thrive.
To support the ambitions of the new centre, GOSH Charity recently launched our first paediatric cancer research strategy. This sees £15 million from our wider £70 million five-year research strategy dedicated to transforming the outcomes and experiences of children with the rarest and hardest to treat cancers.
We are here to give more children the best chance, and the best childhoods, possible. Because we believe no childhood should be lost to serious illness.
Join us, visit www.gosh.org today.